2jix

From Proteopedia

proteopedia linkproteopedia link

spinqualitylabelsall models 2jix, resolution 3.20Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image

CRYSTAL STRUCTURE OF ABT-007 FAB FRAGMENT WITH THE SOLUBLE DOMAIN OF EPO RECEPTOR

Contents 1 Overview 2 Disease 3 About this Structure 4 Reference

Overview

Recombinant human erythropoietin (rHu-EPO) is used to treat anemia by activating the erythropoietin receptor (EPOR) in erythroid progenitor cells, leading to proliferation and differentiation into mature red blood cells. To allow less frequent dosing, a hyperglycosylated version of EPO has been developed with a longer half-life. In principle, an agonistic antibody targeting EPOR would offer an even longer half-life, support robust monthly dosing, and, unlike EPO products, reduce the risk of pure red cell aplasia. The efficiency of signaling and corresponding potency of previously reported antibody mimics are generally suboptimal compared with EPO and not suitable for clinical use. Here we describe a potent, fully human, agonistic antibody (ABT007) targeting EPOR that supports potent, more sustained, and less pulsatile elevation of hematocrit in a human EPOR-expressing transgenic mouse model compared with standard doses of rHu-EPO while requiring less frequent dosing. Resolution of the crystal structure of the EPOR extracellular domain (ECD) complexed to the ABT007 Fab fragment, determined at 0.32 nm, identifies a binding site that is consistent with a novel mechanism of receptor activation based on a unique antibody-imposed conformational change. These results demonstrate that a symmetric molecule can serve as a potent activator of the EPOR.

Disease

Known disease associated with this structure: Erythrocytosis, familial OMIM:[133171]

About this Structure

2JIX is a Protein complex structure of sequences from Escherichia coli. Full crystallographic information is available from OCA.

Reference

A potent erythropoietin-mimicking human antibody interacts through a novel binding site., Liu Z, Stoll VS, Devries PJ, Jakob CG, Xie N, Simmer RL, Lacy SE, Egan DA, Harlan JE, Lesniewski RR, Reilly EB, Blood. 2007 Oct 1;110(7):2408-13. Epub 2007 Jul 9. PMID:17620453

Page seeded by OCA on Thu Feb 21 18:04:08 2008